🇺🇸 Vinblastin in United States

114 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neutropenia — 14 reports (12.28%)
  2. Nausea — 13 reports (11.4%)
  3. Off Label Use — 13 reports (11.4%)
  4. Fatigue — 12 reports (10.53%)
  5. Diarrhoea — 11 reports (9.65%)
  6. Febrile Neutropenia — 11 reports (9.65%)
  7. Anaemia — 10 reports (8.77%)
  8. Myelodysplastic Syndrome — 10 reports (8.77%)
  9. Product Use Issue — 10 reports (8.77%)
  10. Thrombocytopenia — 10 reports (8.77%)

Source database →

Vinblastin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Vinblastin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Vinblastin in United States?

The Lymphoma Academic Research Organisation is the originator. The local marketing authorisation holder may differ — check the official source linked above.